Reducedin vivobinding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users
David M. Semple, Klaus P. Ebmeier, Michael F. Glabus, Ronan E. O’carroll, Eve C. Johnstone
The British Journal of Psychiatry July 1, 1999 DOI: 10.1192/bjp.175.1.63 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional association study Peer reviewed |
|---|---|
| Sample size | 20 |
| Population | Male regular ecstasy users and well-matched controls |
| Topics | MDMA Serotonin |
| Keywords | Serotonin transporter Dopamine transporter Neurotoxicity Pharmacology |
| Citations | 281 |
| Key findings | Ecstasy users showed a cortical reduction of serotonin transporter binding, particularly in primary sensory-motor cortex, with normal dopamine transporter binding in lenticular nuclei. |
Abstract
Background: The use of MDMA (‘ecstasy’) is common among young people in Western countries. Animal models of MDMA toxicity suggest a loss of serotonergic neurons, and potentially implicate it in the development of significant psychiatric morbidity in humans.
Aims: To test whether long-term use of MDMA can produce abnormalities in cerebral serotonin, but not dopamine, transporter binding measured by single photon emission computed tomography (SPECT) Method Ten male regular ecstasy users and 10 well-matched controls recruited from the same community sources participated in SPECT with the serotonin transporter (SEPT) ligand [ 123 I]-CIT. Dopamine transporter binding was determined from scans acquired 23 hours after injection of the tracer.
Results: Ecstasy users showed a cortical reduction of SERT binding, particularly prominent in primary sensory-motor cortex, with normal dopamine transporter binding in lenticular nuclei.
Conclusions: This cross-sectional association study provides suggestive evidence for specific, at least temporary, serotonergic neurotoxicity of MDMA in humans.